Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Raymond

Showing results (41-50 of 173) with videos related to

Pageof 18
Sort By:
Cancer Treatment Reviews|November 26, 2008
Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancerGhassan El Maalouf, Christophe Le Tourneau, Georges Nicolas Batty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidinVirginie Poindessous, Florence Koeppel, Eric Raymond, et al.
Oncotarget|July 13, 2015
Targeting cancer cell metabolism in pancreatic adenocarcinomaRomain Cohen, Cindy Neuzillet, Annemilaï Tijeras-Raballand, et al.
Targeted Oncology|June 5, 2012
Sunitinib in pancreatic neuroendocrine tumorsEric Raymond, Pascal Hammel, Chantal Dreyer, et al.
Pharmacology & Therapeutics|October 15, 2013
MEK in cancer and cancer therapyCindy Neuzillet, Annemilaï Tijeras-Raballand, Louis de Mestier, et al.
Cancer Metastasis Reviews|February 11, 2011
Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumorsEric Raymond, Timothy Hobday, Daniel Castellano, et al.
Schizophrenia Bulletin|December 5, 2009
How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant associationAmélie M Achim, Michel Maziade, Eric Raymond, et al.
International Journal of Oncology|October 9, 2003
Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cellsVirginie Poindessous, Florence Koeppel, Eric Raymond, et al.
Targeted Oncology|May 3, 2011
Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitorsCatherine Delbaldo, Sébastien Albert, Chantal Dreyer, et al.
Hepatology (Baltimore, Md.)|September 2, 2017
Recent developments of c-Met as a therapeutic target in hepatocellular carcinomaMohamed Bouattour, Eric Raymond, Shukui Qin, et al.
Pageof 18

Showing results (41-50 of 173) with videos related to

Sort By:
Pageof 18
Cancer Treatment Reviews|November 26, 2008
Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancerGhassan El Maalouf, Christophe Le Tourneau, Georges Nicolas Batty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidinVirginie Poindessous, Florence Koeppel, Eric Raymond, et al.
Oncotarget|July 13, 2015
Targeting cancer cell metabolism in pancreatic adenocarcinomaRomain Cohen, Cindy Neuzillet, Annemilaï Tijeras-Raballand, et al.
Targeted Oncology|June 5, 2012
Sunitinib in pancreatic neuroendocrine tumorsEric Raymond, Pascal Hammel, Chantal Dreyer, et al.
Pharmacology & Therapeutics|October 15, 2013
MEK in cancer and cancer therapyCindy Neuzillet, Annemilaï Tijeras-Raballand, Louis de Mestier, et al.
Cancer Metastasis Reviews|February 11, 2011
Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumorsEric Raymond, Timothy Hobday, Daniel Castellano, et al.
Schizophrenia Bulletin|December 5, 2009
How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant associationAmélie M Achim, Michel Maziade, Eric Raymond, et al.
International Journal of Oncology|October 9, 2003
Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cellsVirginie Poindessous, Florence Koeppel, Eric Raymond, et al.
Targeted Oncology|May 3, 2011
Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitorsCatherine Delbaldo, Sébastien Albert, Chantal Dreyer, et al.
Hepatology (Baltimore, Md.)|September 2, 2017
Recent developments of c-Met as a therapeutic target in hepatocellular carcinomaMohamed Bouattour, Eric Raymond, Shukui Qin, et al.
Pageof 18